text_1: Pioglitazone use is not associated with an increased risk of prostate cancer.
text_2: Crude incidences of prostate and pancreatic cancer in pioglitazone users vs nonusers were 453.3 vs 449.3 and 81.1 vs 48.4 per 100,000 person-years, respectively.